SoyChemist writes: "When an FDA committee decided that blockbuster oncology drug Avastin should not be used to treat breast cancer because the risks outweigh the benefits, shares of Genentech stock plummeted. Rather than reciting financial figures, Business Week reporter Arlene Weintraub took a step back and painted a detailed picture of how the biotech company is trying to skirt major industry problems within the field of autoimmune disease research. Wired Science provided further analysis, explaining the importance increasing the variety of avoiding me too drugs, not rushing research, and using a personalized medicine approach."
DEAL: For $25 - Add A Second Phone Number To Your Smartphone for life! Use promo code SLASHDOT25. Also, Slashdot's now on IFTTT. Check it out! Check out the new SourceForge HTML5 Internet speed test! ×